Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning Regimen

Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphoma

Bone Marrow Transplantation volume 31, pages 73–78 (2003)Cite this article

Summary:

This study reports on overall and recurrence-free survival (OS and RFS) of 37 consecutive patients with low- and intermediate-grade NHL receiving a related donor allogeneic BMT using a nonradiation-containing preparative regimen. In addition, transplant-related toxicity and factors influencing outcome are discussed. The preparative regimen consisted of busulfan and cyclophosphamide. Median patient age was 44 years (range 20–55). In all, 18 were female. Median follow-up of surviving patients from BMT was 4.2 years. A total of 25 patients had low-grade, and 12 intermediate grade NHL. Most patients (89%) were treated with at least two different chemotherapy regimens prior to BMT. In all, 22 patients (59%) were transplanted in partial remission, 15 (41%) in complete remission. OS at 12 months was 89% (95% confidence interval (CI) of 79–99%) and 79% (64–93%) at 60 months. RFS at 12 months was 86% (75–97%) and at 5 years 70% (54–86%). Four patients (11%) relapsed. Seven patients (19%) died, six because of treatment-related toxicity and one with relapse. Univariate analysis showed improved OS for younger patients and patients of female gender, suggesting that allogeneic BMT using busulfan–cyclophosphamide as a preparative regimen can achieve disease control and possibly cure patients with NHL particularly younger ones.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545.

    Article  CAS  PubMed  Google Scholar 

  2. Cervantes F, Shu XO, McGlave PB et al. Autologous bone marrow transplantation for non-transformed low grade non-Hodgkin's lymphoma. Bone Marrow Transplant 1995; 16: 387–392.

    CAS  PubMed  Google Scholar 

  3. Bierman PJ, Vose JM, Anderson JR et al. High dose therapy with autologous hematopoietic rescue for follicular low grade non-hodgkin's lymphoma. J Clin Oncol 1997; 15: 445–450.

    Article  CAS  PubMed  Google Scholar 

  4. Krackhardt A, Gribben JG. Stem cell transplantation for indolent lymphoma. Curr Opin Hematol 1999; 6: 388–393.

    Article  CAS  PubMed  Google Scholar 

  5. Shepherd JD, Barnett MJ, Connors JM et al. Allogeneic bone marrow transplantation for poor prognosis non-Hodgkin's Lymphoma. Bone Marrow Transplant 1993; 12: 591–596.

    CAS  PubMed  Google Scholar 

  6. Toze CL, Shepherd JD, Connors JM et al. Allogeneic bone marrow transplantation for low grade lymphoma and chronic lymphocytic leukemia. Bone Marrow Transplant 2000; 25: 605–612.

    Article  CAS  PubMed  Google Scholar 

  7. Van Besien K, Sobocinski KA, Rowlings PA et al. Allogeneic bone marrow transplantation for low grade lymphoma. Blood 1998; 92: 1832–1836.

    CAS  PubMed  Google Scholar 

  8. Verdonck LF, Dekker AW, Lokhorst HM et al. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low grade non-Hodgkin's lymphoma. Blood 1997; 90: 4201–4205.

    CAS  PubMed  Google Scholar 

  9. Van Besien KW, de Lima M, Giralt SA et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft versus lymphoma effect. Bone Marrow Transplant 1997; 19: 977–982.

    Article  CAS  PubMed  Google Scholar 

  10. Jones RJ, Ambinder RF, Piantadosi S et al. Evidence of a graft versus lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649–653.

    CAS  PubMed  Google Scholar 

  11. Verdonck LF. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low grade non-Hodgkin's lymphoma: updated results of the Utrecht experience. Leuk Lymphoma 1999; 34: 129–136.

    Article  CAS  PubMed  Google Scholar 

  12. Schimmer AD, Jamal S, Messner H et al. Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL): results of a provincial strategy. Bone Marrow Transplant 2000; 26: 859–864.

    Article  CAS  PubMed  Google Scholar 

  13. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382–1388.

    CAS  PubMed  Google Scholar 

  14. Copelan EA, Biggs JC, Szer J et al. Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphoblastic leukemia and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2). Semin Oncol 1993; 20 (Suppl. 14): S33–S38.

    Google Scholar 

  15. Brodsky I, Biggs JC, Szer J et al. Treatment of chronic myelogenous leukemia with allogeneic bone marrow transplantation after preparation with busulfan and cyclophosphamide (BuCy2): an update. Semin Oncol 1993; 20 (Suppl. 14): S27–S31.

    Google Scholar 

  16. Van der Jagt RHC, Appelbaum FR, Petersen FB et al. Busulfan and cyclophosphamide as a preparative regimen for bone marrow transplantation in patients with prior chest radiotherapy. Bone Marrow Transplant 1991; 8: 211–215.

    CAS  PubMed  Google Scholar 

  17. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729–735.

    Article  CAS  PubMed  Google Scholar 

  18. Hess AD, Kennedy MJ, Ruvolo PP et al. Antitumor activity of syngeneic/autologous graft versus host disease. Ann N Y Acad Sci 1995; 770: 189–202.

    Article  CAS  PubMed  Google Scholar 

  19. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  20. Mantel N. Evaluation of survival data and two new rank order statistics arising in its considerations. Cancer Chemother Rep 1966; 50: 163–170.

    CAS  PubMed  Google Scholar 

  21. McDonald GB, Hinds MS, Fisher LB et al. Venoocclusive disease of the liver and multi organ failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255–267.

    Article  CAS  PubMed  Google Scholar 

  22. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft versus host disease in human recipients of marrow from HLA matched sibling donors. Transplantation 1974; 18: 295–304.

    Article  CAS  PubMed  Google Scholar 

  23. Shulman HM, Sale GE, Lerner KG et al. Chronic cutaneous graft versus host disease in man. Am J Pathol 1978; 91: 545–570.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. De Magalhaes-Silverman M, Lister J, Rybka W et al. Busulfan and cyclophopshamide (Bu/Cy2) as preparative regimen for patients with lymphoma. Bone Marrow Transplant 1997; 19: 777–781.

    Article  CAS  PubMed  Google Scholar 

  25. Weaver CH, Schwartzberg L, Rhinehart S et al. High dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low grade non-Hodgkin's lymphoma. Bone Marrow Transplant 1998; 21: 383–389.

    Article  CAS  PubMed  Google Scholar 

  26. Avalos BR, Klein JL, Kapoor N et al. Preparation for marrow transplantation in Hodgkin's disease and non-Hodgkins lymphoma using Bu/Cy. Bone Marrow Transplant 1993; 12:133–138.

    CAS  PubMed  Google Scholar 

  27. Appelbaum FR, Anderson JA. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia 1998; 12 (Suppl. 1): S25–S29.

    PubMed  Google Scholar 

  28. Andersson BS, Gajewski J, Donato M et al. Allogeneic stem cell transplantation for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy). Bone Marrow Transplant 2000; 26 (Suppl. 2): S35–S38.

    Article  Google Scholar 

  29. Ringden O, Remberger M, Ruutu T et al. Increased risk of chronic graft versus host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic bone marrow transplantation group. Blood 1999; 93: 2196–2201.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We acknowledge the dedication and work of all health-care professionals and support staff caring for allogeneic transplant patients at Princess Margaret Hospital.

Author information

Authors and Affiliations

  1. Department of Medical Oncology and Hematology, Bone Marrow Transplant Service, Princess Margaret Hospital/University Health Network, University of Toronto, Toronto, Ontario, Canada

    T L Kiss, H A Messner, J Meharchand, A D Schimmer & J H Lipton

  2. Department of Biostatistics, Princess Margaret Hospital/University Health Network, University of Toronto, Toronto, Ontario, Canada

    T Panzarella

  3. Division of Hematology/Oncology, University of Florida, Gainesville, FL, USA

    V Reddy

Authors
  1. T L Kiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T Panzarella
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H A Messner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Meharchand
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V Reddy
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A D Schimmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J H Lipton
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kiss, T., Panzarella, T., Messner, H. et al. Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 31, 73–78 (2003). https://doi.org/10.1038/sj.bmt.1703790

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703790

Keywords

This article is cited by

Search

Advanced search

Quick links